选择性PPARδ激动剂塞拉德尔帕治疗原发性胆汁性胆管炎的长期疗效与安全性:ASSURE interim研究结果
ASSURE是一项正在进行的开放标签长期研究,评估选择性过氧化物酶体增殖物激活受体δ激动剂塞拉德尔帕在原发性胆汁性胆管炎中的长期疗效与安全性。从RESPONSE研究或早期塞拉德尔帕研究转入的患者纳入分析;RESPONSE完成时复合生化应答率塞拉德尔帕组为62%(79/128)、安慰剂组为20%(13/65),在ASSURE治疗12个月后继续塞拉德尔帕组为72%(21/29)、交叉塞拉德尔帕组为94%(15/16),未报告塞拉德尔帕相关严重不良事件。
要点
- RESPONSE完成时复合生化应答率塞拉德尔帕组62%(79/128) vs 安慰剂组20%(13/65)。
- ASSURE治疗12个月后,继续塞拉德尔帕组应答率72%(21/29),交叉塞拉德尔帕组94%(15/16)。
- 基线瘙痒NRS≥4的塞拉德尔帕组NRS下降在额外6个月治疗后维持(-3.4至-3.8)。
核心结论
- 塞拉德尔帕在原发性胆汁性胆管炎患者中显示胆汁淤积生物标志物和瘙痒的持久改善,治疗最长可达2年,长期使用总体安全。
研究设计与样本
- 正在进行的开放标签长期疗效与安全性ASSURE研究(ClinicalTrials.gov: NCT03301506)的interim分析。
- 患者来自3期随机安慰剂对照12个月RESPONSE研究或既往参与早期塞拉德尔帕研究的患者。
- interim截止时337例患者入组并接受至少1剂塞拉德尔帕10 mg:RESPONSE研究安慰剂治疗54例、塞拉德尔帕治疗104例,早期研究179例。
主要发现
- RESPONSE完成时复合生化应答率塞拉德尔帕组为62%(79/128),安慰剂组为20%(13/65)。
- ASSURE治疗12个月后,从RESPONSE转入的患者中继续塞拉德尔帕组应答率为72%(21/29),交叉塞拉德尔帕组为94%(15/16)。
- 早期研究患者在ASSURE治疗12个月和24个月后应答率分别为73%(120/164)和70%(69/99)。
- 基线NRS≥4的塞拉德尔帕治疗患者在RESPONSE完成时NRS下降-3.4,额外6个月治疗后维持为-3.8;交叉塞拉德尔帕组(-3.8)和早期研究患者(-3.5)在ASSURE治疗6个月后变化相似。
- 未报告塞拉德尔帕相关严重不良事件。
关键数值与推荐
- 复合生化应答定义:碱性磷酸酶<1.67倍正常上限、总胆红素≤正常上限且碱性磷酸酶下降≥15%。
- 瘙痒评估采用瘙痒数字评定量表(NRS),分析基线评分≥4的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The objective of these analyses was to evaluate interim data from the ongoing, open-label, long-term efficacy and safety ASSURE study of seladelpar, a selective peroxisome proliferator-activated receptor δ agonist, in primary biliary cholangitis. METHODS: Patients rolling over from the phase 3, randomized, placebo-controlled, 12-month RESPONSE study or with previous participation in earlier legacy seladelpar studies were enrolled. Interim evaluations included composite biochemical response (alkaline phosphatase <1.67 upper limit of normal, total bilirubin ≤ upper limit of normal, and alkaline phosphatase decrease ≥15%), pruritus numerical rating scale (NRS) change among patients with a baseline score ≥4, and safety. RESULTS: At interim cutoff, 337 patients were enrolled and received ≥1 seladelpar 10 mg dose: 54 placebo-treated and 104 seladelpar-treated from RESPONSE and 179 from legacy studies. The composite response rate at RESPONSE completion was 62% (79/128) with seladelpar and 20% (13/65) with placebo. After 12 months in ASSURE, among patients who rolled over from RESPONSE, response rates were 72% (21/29) in patients continuing seladelpar and 94% (15/16) in crossover seladelpar patients. In legacy trial patients, response rates were 73% (120/164) and 70% (69/99) after 12 and 24 months of treatment in ASSURE, respectively. The NRS decrease at RESPONSE completion in seladelpar-treated patients with baseline NRS ≥4 (-3.4) was maintained after 6 additional months of treatment (-3.8); changes were similar in crossover seladelpar (-3.8) and legacy patients (-3.5) after 6 months of treatment in ASSURE. No seladelpar-related serious adverse events were reported. DISCUSSION: Seladelpar demonstrated durable improvements in cholestatic biomarkers and pruritus in patients with primary biliary cholangitis with up to 2 years of treatment and remained overall safe with long-term use. Clinicaltrials.gov: NCT03301506.
引用
- Levy C, Trivedi PJ, Kowdley KV, et al. Long-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results. Am J Gastroenterol. 2025. PMID: 40553148. doi:10.14309/ajg.0000000000003603
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。